Monthly Prescribing Reference

Skyrizi Now Available as a Single-Dose Injection for Plaque Psoriasis

Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...
Nasdaq

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Healio

Skyrizi 150 mg injection available for plaque psoriasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Skyrizi is now available as a single-dose 150 mg ...
Nasdaq

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating ...
Healio

FDA approves Skyrizi for moderate to severe plaque psoriasis

Please provide your email address to receive an email when new articles are posted on . AbbVie announced that the FDA has approved Skyrizi, an interleukin-23 inhibitor for treating moderate to severe ...
Seeking Alpha

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...
FiercePharma

AbbVie's Skyrizi nabs psoriatic arthritis nod, its 2nd, shortly after Rinvoq

After Rinvoq won two new indications in as many months, AbbVie's immunology compatriot Skyrizi is getting in on the approval action. Skyrizi clinched a second nod, this time to treat adults with ...
Reuters

AbbVie sees strong 2022 earnings as Botox, Skyrizi power profit beat

Feb 2 (Reuters) - AbbVie Inc (ABBV.N), opens new tab forecast full-year adjusted profit above Wall Street estimates on Wednesday, as strong sales of its blockbuster anti-wrinkle injection Botox and ...
Seeking Alpha

AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis

NORTH CHICAGO, Ill., Aug. 28, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and ...
RAPS

FDA Approvals Roundup: Kimmtrak, Skyrizi, Veklury

Immunocore’s Kimmtrak (tebentafusp-tebn; injection) has been approved for treating unresectable or metastatic uveal melanoma (mUM) in adults who are HLA-A*02:01 positive and have not received previous ...
St. Louis American

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie’s Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...